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ABBREVIATIONS 
Abbreviation Full name 
 
AC adenylyl cyclase 
ATP adenosine triphosphate  
β-AR β-adrenergic receptors 
bp base pair 
cAMP adenosine-3’,5’-cyclic monophosphate 
cDNA complementary DNA 
CE capillary electrophoresis 
c-Myc complementary myelocytomatosis 
CNS central nervous system 
5-CT 5-carboxamidotryptamine 
dATP deoxyadenosine-5’-triphospate 
ddNTP dideoxyribonucleoside triphosphate 
dNTP deoxyribonucleoside triphosphate 
DNA deoxyribonucleic acid 
EL extracellular loop 
EPR EP prostaglandin receptor 
ERK extracellular signal-regulated kinase 
GPCRs G-protein-coupled receptors 
GDP guanosine-5’-diphosphate 
GTP guanosine-5’-triphosphate 
Gs protein stimulatory G protein 
h human 
HA hemagglutinin 
HEK human embryonic kidney 
5-HT 5-hydroxytryptamine 
IC intracellular 
kb kilobase 
mRNA messenger ribonucleic acid 
OD optical density 
ORF open reading frame 
pcDNA plasmid complementary DNA 
PCR polymerase chain reaction 
PKA protein kinase A 
PLC phospholipase C 
PNS peripheral nervous system 
RNA ribonucleic acid 
SCN suprachiasmatic nucleus 
SR split receptor 
TAE Tris-acetate EDTA 
TM transmembrane 
TMDs transmembrane domains 
YFP yellow fluorescent protein 
UV-light ultraviolet light 
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1. SUMMARY 
Unlike other G-protein-coupled receptors the human 5-HT7 receptor reduces the signalling 
through other receptors when expressed together in cells (Bruheim et al., 2003;Andressen et 
al., 2006). To understand this unusual property of the 5-HT7 receptor, we aim to determine the 
key amino acid sequences of the 5-HT7 receptor which are responsible for the attenuation of 
signalling through other Gs-coupled receptors. 
 
As a first step to determine the key amino acid sequences of the 5-HT7 receptor responsible 
for this attenuation we constructed chimerae of the 5-HT7 receptor and another serotonin 
receptor which does not display this unusual property, the 5-HT4 receptor. Plasmids encoding 
the 5-HT7 and 5-HT4 receptors were engineered using molecular biology techniques to 
achieve the (recombinant) plasmids encoding the desired chimeric receptors.  
 
 
A strategy involving insertion of restriction sites for the restriction endonuclease BsiWI was 
employed to construct chimeric receptors of human (h) 5-HT7(b) and h5-HT4(b). The 
mutagenesis primers for the respective receptors were designed using the computer software 
SE Central designed for cloning.  
 
The plasmids were mutated by two methods. Mutation in extracellular loop 2 was performed 
by method I (Gene TailorTM Site-Directed Mutagenesis System) and mutation in extracellular 
loop 1 was performed by method II (Standard mutagenesis strategy). Once the plasmids 
containing the receptor genes were mutated, they were subsequently cut by endonuclease 
enzymes. The cut DNA fragments were interchanged and ligated with the opposite parts from 
both receptor types. The recombinant DNA was verified by both restriction digestion and 
sequencing. 
 
Chimeric receptor constructs based on cutting in extracellular loop 1 (EL1) of the receptors 
were successfully made. The constructed chimers were 5-HT7 up to EL1, 5-HT4 from EL1 
and 5-HT4 up to EL1, 5-HT7 from EL1. Chimeric receptor constructs based on cutting in 
extracellular loop 2 (EL2) were also made, but sequencing revealed that a string of 10 bp had 
been lost. The constructed chimeric receptors will subsequently be expressed in HEK293 cells 
and their pharmacological properties determined by binding and adenylyl cyclase assays. 
  Introduction 
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2. INTRODUCTION 
2.1 G-PROTEIN-COUPLED RECEPTORS 
2.1.1 General structure and classification of the G-protein-coupled receptors 
G-protein-coupled receptors (GPCRs) are the most numerous and versatile family of proteins 
that control cell-cell communications. Their endogenous ligands include hormones, 
neurotransmitters, growth and survival factors. Exogenous factors such as smells, tastes and 
photons also act as ligands for the GPCRs. (Joubert et al., 2002). 
 
All the GPCRs have an extracellular N-terminal segment, seven transmembrane domains 
(TMDs) which form the TM core, three extracellular loops (exoloops), three intracellular 
loops (cytoloops) and an intracellular C-terminal segment (Fig.1). The C-terminal segment 
can be palmitoylated at a cystein residue, thus forming a fourth cytoloop. Each of the seven 
TMDs is generally composed of 20-27 amino acids, whereas the N-terminal segments vary 
from 7-595 amino acids, the loops from 5-230 amino acids and the C-terminal segments from 
12-359 amino acids. These variations in size specify their diverse structures and functions (Ji 
et al., 1998). 
 
Odd numbers of TMDs place the N- and C- terminal segments at opposite membrane 
surfaces. It allows glycosylation and ligand binding at the N-terminal segment, and 
phosphorylation and palmitoylation at the C-terminal segment for desensitization and 
internalization. It seems like the seven TMDs may be the minimum necessary to form six 
loops and therefore gives the TM core a sufficient size and versatility. The structure of 
GPCRs offers a prodigious number of specificities, regulatory mechanisms, and contact sites 
for G-protein and other signal molecules such as Jak2 kinase, phospholipase Cγ, GPCR-
kinases, arrestin, calmodulin and/or protein kinase C.  
 
The TM core is tightly packed by hydrogen bonds and salt bridges, leaving no room for a 
channel or tunnel structure (Ji et al., 1998). 
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Figure 1. Schematic presentation of the general structure of G-protein coupled receptors (GPCRs).  
Adapted from (Ji et al., 1998) 
 
2.1.2 Ligand binding and signal generation 
Individual GPCRs can signal through several G-protein subtypes and through G-protein-
independent pathways, often in a ligand-specific manner. This functional plasticity can be 
attributed to structural flexibility of the GPCRs and the ability of the ligands to induce or 
stabilize ligand-specific conformations. Ligands for a given GPCR can show different 
efficacy profiles for coupling to distinct signalling pathways.    
            
Recent studies suggest that agonist binding and receptor activation occur through a series of 
conformational intermediates (Fig.2). Transition to these intermediate states involves the 
disruption of non-covalent intramolecular interactions that stabilize the basal state of the 
receptor. Binding of structurally different agonists might entail the disruption of different 
combinations of these intramolecular interactions, leading to different receptor conformations 
and differential effects on downstream signalling proteins (Kobilka and Deupi, 2007). 
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Figure 2. Possible mechanisms by which agonist binding disrupts intramolecular interactions that 
stabilize the inactive GPCR state. (a) The agonist (yellow) binds directly to amino acids involved in 
stabilizing the inactive receptor (red, green, blue) state. (b) Agonist binding stabilizes a new set of 
intramolecular interactions. Adapted from (Kobilka and Deupi, 2007). 
 
2.2 HETEROTRIMERIC G PROTEINS 
When an extracellular agonist binds to a GPCR, the receptor undergoes a conformational 
change that enables it to activate heterotrimeric GTP-binding proteins (G proteins). These 
G proteins reside at the cytoplasmic face of the plasma membrane, where they serve as relay 
molecules, functionally coupling the receptors to enzymes or ion channels in the membrane. 
There are various types of G proteins, each specific for a particular set of GPCRs and for a 
particular set of downstream target proteins in the plasma membrane. 
 
G-proteins are composed of three protein subunits – α, β, and γ. In the unstimulated state, the 
α-subunit has GDP bound and the G protein is inactive. When stimulated by an activated 
receptor, the α-subunit releases its bound GDP, allowing GTP to bind in its place. This 
exchange causes the trimer to dissociate into two activated components, the α-subunit and the 
βγ-complex.     
 
The dissociation of the trimeric G-protein activates its two components in different ways. 
GTP-binding causes a conformational change that affects the surface of the α-subunit that 
Introduction 
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associates with the βγ-complex in the trimer. This change causes the release of the βγ-
complex, but it also causes the α-subunit to adopt a new shape that allows it to interact with 
its target proteins. The βγ-complex does not change its conformation, but the surface previously 
masked by the α-subunit is now available to interact with a second set of target proteins. The α-
subunit is a GTPase, and once it hydrolyzes its bound GTP to GDP, it reassociates with a βγ 
complex to reform an inactive G protein, reversing the activation process. 
Both the α-subunit and βγ-complex can regulate the activation and inhibition of different G 
protein-coupled effector molecules (The Cell, 4th ed. Pg 852-856). 
 
G-proteins are divided into four subfamilies, depending on their α-subunit: 1) The ‘Gs’ 
subfamily that stimulates adenylyl cyclase (AC), 2) the ‘Gi/o’ subfamily that inhibits AC and 
regulates ion channels, 3) the ‘Gq/11’ subfamily that activates phospholipase Cβ and 4) the 
‘G12/13’ subfamily that has been shown to activate a small GTPase, Rho. Depending on the 
subtype(s) of the G protein that a given GPCR interacts with, a single or a combination of 
effectors can be activated (Wong, 2003).There are a number of subtypes of β- and γ-subunits, 
too. A combination of different subtypes of α-, β- and γ- subunits provides a great diversity of 
intracellular signalling pathways that can be regulated by GPCRs (Wong, 2003). 
 
2.3 5-HT  
Serotonin (5-hydroxytryptamine; 5-HT) is an endogenous monoamine synthesised from the 
amino acid tryptophan mainly in the enterochromaffin cells of the intestine (95%) and the rest 
in discrete areas of the brain and neuroendothelial cells lining the lung. Tryptophan is 
converted to 5-hydroxytryptophan by tryptophan hydroxylase. The 5-hydroxytryptophan is 
then decarboxylated by an amino acid decarboxylase to 5-hydroxytryptamine.  
 
5-HT plays a crucial role in a number of physiological and pathological processes in many 
organs including the brain, gastrointestinal tract, heart, blood cells and vessels. It acts both as 
a neurotransmitter and as a local hormone in the peripheral vascular system (Rang et al., 
2003). The physiological effects of the 5-HT in different blood vessels or different parts of the 
heart depend on the 5-HT receptors involved, the intracellular signals evoked through these 
receptors, and their cellular localisation (Kaumann and Levy, 2006b). 
  
  Introduction 
 11
The mechanisms of synthesis, storage, release and reuptake of 5-HT are very similar to that of 
noradrenaline, and many drugs affect both processes indiscriminately. Degradation of 5-HT 
occurs mainly through oxidative deamination, catalysed by monoamine oxidase, followed by 
oxidation to 5-hydroxyindoleacetic acid (5-HIAA), the pathway being the same as that of 
noradrenaline catabolism (Rang et al., 2003). 
 
5-HT has diverse effects on the cardiovascular system. The hormone displays both 
vasodilation and vasoconstriction depending on the vessel site mediated through different 5-
HT receptor subtypes (Rang et al., 2003). In the heart, 5-HT can elicit cardioexcitation, such 
as increased inotropic and chronotropic effects, through a direct action on the heart (Kaumann 
and Sanders, 1998;Brattelid et al., 2004) and cardiodepression indirectly via stimulation of the 
central nervous system (Kaumann and Sanders, 1998). 
 
Although 5-HT is synthesized by only a small group of neurons within the raphe nuclei of the 
brain stem, these cells send both ascending and descending projections to large parts of the 
CNS. Because of this widespread innervation, 5-HT has been implicated in numerous 
important physiological and pathophysiological phenomena, including sleep-wakefulness 
cycles and several psychiatric disorders (Hoyer et al., 2002;Hedlund and Sutcliffe, 2004). 
  
2.4 5-HT RECEPTORS 
Among known neurotransmitters, 5-HT acts on the most diverse group of receptors. 5-HT 
exerts its effects via fourteen different receptor subtypes. All of them are G protein-coupled 
receptors, with the exception of 5-HT3 receptors, which are ligand-gated cation-channels. The 
5-HT receptors act primarily by means of the following second messenger systems: 5-
HT1A,B,D,E,F receptors decrease cyclic AMP (cAMP) formation; 5-HT2A,B,C receptors increase 
inositol triphosphate and diacylglycerol formation; 5-HT3 receptors increase Na+- and Ca2+-
influx (Barnes and Sharp, 1999)and 5-HT4 receptors increase cAMP formation (Kaumann, 
1990).The physiological effector system for 5-HT5A,B receptors remains elusive, although 
iniositol triphosphate and diacylglycerol formation have been implicated in transfected 
cells{Francken, 2000 3997 /id}. The 5-HT6,7 receptors are positively coupled to adenylyl 
cyclase and increase cAMP formation (Barnes and Sharp, 1999). 
 
The 5-HT7 receptors are widely expressed in different cell types in the central nervous system 
and in peripheral tissues. Genetic and pharmacological studies have provided evidence that 5-
Introduction 
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HT7 receptors may be involved in regulation of emotions, thermoregulation, circadian 
rhythmicity, memory processes and smooth muscle relaxation(Vanhoenacker et al., 2000). 
 
2.5 5-HT4 RECEPTORS 
5-HT4 receptors occur in the brain, as well as in peripheral organs, such as the gastrointestinal 
tract, bladder and heart. One of their main physiological roles appears to be in the 
gastrointestinal tract, where they produce neuronal excitation and mediate the effect of 5-HT 
in stimulating peristalsis (Rang et al., 2003). Experimental studies have shown that 5-HT 
through 5-HT4 receptors exerts positive chronotropic and inotropic effects in human and 
porcine cardiac atria (Kaumann and Sanders, 1998). 
 
The human 5-HT4 receptor exists in multiple splice variants, 5-HT4 (a-g) and 5-HT4 (n). They are 
identical up to Leu 358, followed by different C-terminal tails. 5-HT4(hb) is a splice variant 
which is a result of  an extra exon "h" giving an insertion of 14 amino acid in the second 
extracellular loop (Fig.3). Exon h was only observed in combination with the 5-HT4(b) tail and 
therefore the receptor was named 5-HT4(hb) {Brattelid, 2004 1951 /id; Bender, 2000 2153 /id} 
 
It seems like the 5-HT4 (b) splice variant is the dominant splice variant in all human tissues 
examined, including the human heart tissue(Medhurst et al., 2001).  
 
The 5-HT4 receptors are positively coupled to the Gs protein-adenylyl cyclase system which 
leads to increased cAMP level in the cell (Langlois and Fischmeister, 2003). 
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Figure 3. Structure of the human 5-HT4(b) receptor amino acid sequence. The 5-HT4(hb)  splice variant 
has an extra 14 amino acid  extracellular loop, indicated with "h". Adapted from (Kaumann and Levy, 
2006a) 
 
2.6 5-HT7 RECEPTORS 
The 5-HT7 receptors are the most recently identified member of the 5-HT receptor family and 
has been characterized on the basis of structural, operational and transductional 
characteristics. It has been cloned from various species such as human, rat, mouse, pig, guinea 
pig and Xenopus laevis. The 5-HT7 receptors are positively linked to adenylyl cyclase 
(Vanhoenacker et al., 2000).  
 
Alternative splicing of the human gene has been reported to generate three 5-HT7 receptor 
isoforms (5-HT7a,b,d), which differ in their C-termini. The amino acid sequence of the 5-HT7(b) 
receptor is shown in figure 4. To date, these isoforms show no major differences in their 
respective pharmacology and signal transduction properties (Heidmann et al., 1998;Krobert et 
al., 2001). 
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Figure 4. Structure of the human 5-HT7(b) receptor amino acid sequence. Adapted from (Heidmann et 
al., 1997). 
 
Pharmacologically, the 5-HT7 receptor shows high affinity for 5-carboxamidotryptamine (5-
CT) and 5-hydroxytryptamine (5-HT). Several antipsychotics and antidepressants have high 
affinity for the 5-HT7 receptors. Several antidepressants, both tricyclic antidepressants and 
selective 5-HT reuptake inhibitors (SSRIs), induced c-fos expression in rats in a manner 
consistent with 5-HT7 receptor activation within the suprachiasmatic nucleus (SCN) of the 
hypothalamus. The 5-HT7 receptors are involved in thermoregulation, circadian rhythm, 
learning and memory, hippocampal signalling, sleep and endocrine regulation (Hedlund and 
Sutcliffe, 2004). 
 
5-HT7 receptor signalling 
When expressed in cell lines, the 5-HT7 receptors display pharmacological properties 
consistent with tight association with the G protein, regardless of agonist binding (Bruheim et 
al., 2003). Activation of the G protein Gs leads to activation of adenylyl cyclase and a rapid 
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increase in the formation of the intracellular second messenger cAMP. This elevation of 
cAMP level has several intracellular effects, such as activation of cAMP-dependent protein 
kinase (PKA) and exchange proteins directly activated by cAMP (Epacs), guanine nucleotide 
exchange factors specific for Rap (Vossler et al., 1997;de Rooij et al., 1998;Kawasaki et al., 
1998). 
 
The 5-HT7 receptors activate the extracellular signal-regulated kinase (ERK) through a 
mechanism that is dependent on a Ras monomeric GTPase (Norum et al., 2003). Activation of 
the 5-HT7 receptors stimulate ERK in hippocampal neurons, an effect that can be of 
importance for hippocampal function and mood regulation (Errico et al., 2001). 
 
 
2.7 BACKGROUND AND PURPOSE OF THE PRESENT STUDY  
Previous studies on Human Embryonic Kidney (HEK) 293 cells revealed that activation of 
adenylyl cyclase by other endogenous Gs-coupled receptors is attenuated by the 5-HT7 
receptors when the receptors are expressed together in the cells. Using the ecdysone-inducible 
expression system, which allows the titration of increasing receptor density in the same clonal 
cell line, the effects of 5-HT4(b) and 5-HT7(a,b,d) receptor expression on adenylyl cyclase (AC) 
stimulation by the endogenous Gs-coupled β-adrenergic(βAR) and prostanoid EP (EPR) 
receptors were compared. The conclusion of the study was that βAR and EPR-stimulated AC 
activity was attenuated by 5-HT7 receptor expression in both membrane preparations and 
intact HEK293 cells (Fig.5). At the same time the βAR and EPR-stimulated AC activity was 
unaffected by expression of the Gs-coupled 5-HT4 receptor (Andressen et al., 2006). Based on 
these data the present study was designed.  
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Figure 5. The figure illustrates the cellular mechanisms of the receptors 5-HT7, βAR and EPR 
expressed together in HEK293 cells. (Designed by Cam Hong Thi Nguyen, 2007) 
 
 
The ultimate aim of the research program of which the present study is a part is to determine 
the molecular properties of the 5-HT7 receptor which leads to this unusual property of 
attenuation of the signalling through other endogenous Gs-coupled receptors. To achieve this 
goal we want to construct chimeric receptors of 5-HT7.  
 
Since the βAR and EPR-stimulated AC activity was unaffected by expression of the Gs-
coupled 5-HT4(b) receptor this receptor seems to be a very good candidate in construction of 
the chimers of 5-HT7. The chimers will contain parts of the 5-HT4(b) receptor and the 5-HT7(b) 
receptor. 
 
The constructed chimeric receptors will subsequently be expressed in HEK293 cells and their 
pharmacological properties determined by binding and adenylyl cyclase assays. 
 
AC
Gs Gs Gs
ATP        cAMP 
β-AR5-HT7 Prostaglandin
?
 
 
? 
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3. MATERIALS AND METHODS 
3.1 VECTORS UTILIZED 
pcDNA 3.1 vectors  
The pcDNA3.1(+) and pcDNA3.1(-) (Invitrogen®) are 5.4 kb vectors derived from pcDNA3 
and designed for high-level stable and transient expression in mammalian host cells such as 
HEK293 cells. The vectors contain multiple cloning sites in the forward (+) and reverse (-) 
orientations to facilitate cloning.   
 
The plasmid 3xHA-5-HT4(b) contains an N-terminally hemagglutinin-tagged 5-HT4(b) receptor 
coding sequence cloned into pcDNA3.1(+) at KpnI (5’) and XhoI (3’). The plasmid was 
purchased from cDNA.org. 
 
The plasmid c-myc-5-HT7(a) contains an N-terminally myc-tagged 5-HT7(a) receptor coding 
sequence cloned into pcDNA3.1(+) at BamHI (5’) and EcoRI (3’)(De Martelaere et al., 
2007) . This plasmid was kindly provided by Dr. Peter Vanhoenacker, Ghent, Belgium.  
 
The plasmid 5-HT7(b) YFP contains the coding sequence of the human 5-HT7(b) receptor fused 
with a coding sequence for the C-terminal fluorescent protein called (enhanced) Yellow 
Fluorescent Protein, cloned into pcDNA3. When expressed in HEK293 cells and examined by 
fluorescence microscopy these proteins emit a yellow light showing the location and the 
movement of the 5-HT7(b) in the cells. For the construction of 5-HT7(b)YFP, a SalI-flanked 
primer with a mutated stop codon was used to generate a PpuMI/ SalI fragment covering the 
C-terminal end of the 5-HT7(b) receptor. After subcloning and sequence verification, this 
PpuMI/ SalI fragment was ligated to a PpuMI/ XbaI fragment of ph5- HT7(b)(De Martelaere 
et al., 2007) and a SalI/XbaI fragment of peYFPN1 (Clontech®). The resulting vector was 
sequence verified in both directions (Andressen et al. 2007, submitted). This plasmid was also 
kindly provided by Dr. Peter Vanhoenacker, Ghent, Belgium. 
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3.2 GENERAL EXPERIMENTAL DESIGN IN CONSTRUCTING 
CHIMERIC RECEPTORS 
To construct chimeric receptors of h5-HT7 and h5-HT4 several different reactions are made 
along with simulation from the computer software designed for cloning. The software called 
SE Central enables the designer to make all kinds of gene alterations on the computer before 
performing the reactions in the laboratory. 
 
First the mutagenesis is planned on the receptor genes by using the software programme in 
order to introduce a cutting site for a restriction endonuclease enzyme (BsiWI) in the h5-HT7 
receptor and h5-HT4 receptor. The enzyme BsiWI was chosen as the restriction enzyme since 
this enzyme was one of the two enzymes found which does not cut the receptors within the 
loops. Then the mutation primers for the respective genes are designed by the same software 
programme. A Polymerase Chain Reaction is run with the designed mutagenesis primers to 
clone the receptor genes with mutation. The mutated genes are separated by agarose gel 
electrophoresis, transformed into bacterial cells to be circularized and cut by restriction 
digestion using restriction endonuclease enzymes. 
 
The cut DNA fragments are separated by agarose gel electrophoresis and purified by gel 
extraction. The DNA fragments from both receptors are interchanged and ligated with the 
opposite parts from both receptor types. The ligated gene products are transformed into 
TOP10 cells and amplified. The recombinant gene products are then sequenced to verify if the 
reactions proceeded as expected. The sequencing results reveal the information of the exact 
chimeric receptor gene sequence. The recombinant gene products are also analyzed 
qualitatively by restriction digestion and separation on agarose gel. 
 
The restriction cuts were made within the extracellular loops 1 and 2 of the h5-HT7 and h5-
HT4 receptors. The mutagenesis reaction was carried out by different methods for the two 
extracellular loops. 
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3.3 MUTAGENESIS REACTION 
The mutagenesis primers were first designed by the software program SE central and the 
designed primers were supplied by Invitrogen®.  The mutagenesis reaction by method I 
(3.2.2) was performed according to the protocol from Invitrogen® (“Gene TailorTM Site-
Directed Mutagenesis System”). The mutagenesis reaction by method II (3.2.4) was 
performed according to the protocol for Standard Mutagenesis Strategy. 
 
3.3.1 Primer design 
Design of good mutagenesis primers is critical in order to get specific and effective 
amplification of the target gene as well as to avoid amplification of unwanted DNA sequences 
due to primer dimers or unspecific binding of the primers.  
 
To design the mutagenesis primers for the “Gene TailorTM Site-Directed Mutagenesis 
System” (3.2.2) the following specifications by Invitrogen® were followed:  
 
• Both primers (forward and reverse) should be approximately 30 nucleotides in length, 
not including the mutation site on the mutagenic primer. 
• Primers should have an overlapping region at the 5´ends of 15-20 nucleotides, for 
efficient end-joining of mutagenesis product. 
• The mutation site should be located on only one of the primers, downstream from and 
adjacent to the overlapping region, and can be up to 21 bases (deletions, insertions, and / 
or any substitutions). 
• On the mutagenic primer, there should be at least 10 nucleotides downstream of the 
mutation site for efficient annealing. 
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Example of a mutagenesis primer design: 
 
The mutation can be located on either primer. 
 
The mutagenesis primers for method II (3.2.4) were designed with mutations located on both 
primers (forward and reverse).  
 
3.3.2 Method I: Gene TailorTM Site-Directed Mutagenesis System 
The “Gene TailorTM Site-Directed Mutagenesis System” Invitrogen® is a simple and highly 
efficient method for standard and high-throughput in vitro site-directed mutagenesis.  This 
unique system can generate base substitutions, deletions, or insertions of up to 21 nucleotides 
in DNA plasmids of up to 8 kb from any source, with no specialized vectors, host strains, or 
restriction sites required. Only one mutagenic oligonucleotide primer is required to generate a 
mutation site. The high efficiency (>80%) and simplified protocols of the kit allow for the 
generation of site-directed mutants from the same or different target genes. The mutagenesis 
system relies on the inherent properties of the enzymes DNA methylase and McrBC. 
 
In this study the PCR is used to amplify the plasmid in a mutagenesis reaction with two 
overlapping primers, one of which contains the target mutation. The PCR product obtained is 
a linear double stranded DNA containing the mutation. 
 
Figure 6 is a workflow diagram showing the different processes involved in this mutagenesis 
system. In the PCR the mutagenesis primers anneal to the methylated plasmid and amplify the 
plasmid with a mutation. The product which is a linear double-stranded DNA containing 
mutation is further transformed into E. coli cells to be circularized. 
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Figure 6. Mutagenesis workflow diagram (Adapted from Invitrogen® “Gene TailorTM Site-Directed 
Mutagenesis System” user manual). 
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Protocol for methylation reaction 
 
Reagent Single reaction 
Plasmid DNA 100 ng 
Methylation buffer 1.6 μl 
10x S-adenosylmethionine(SAM) 1.6 μl 
DNA methylase (4U/ μl) 1.0 μl 
Sterile, distilled water  to 16 μl 
 
1. Combine reagents and incubate at 37º C for 1 hour. 
2. After methylation, proceed to Mutagenesis reaction by PCR. 
The protocol of the mutagenesis reaction is integrated in a worksheet as the example below. 
 
Example of a worksheet used for the PCR reaction: 
Stock conc. Conc. in assay
PCR Buffer (X) 10 1 Date of experiment 15.2.07
MgSO4 (mM) 50 1
dNTP's (mM) 10 0.3 ID
Polymerase (U/µl) 5 1.5 Polymerase Plat.Taq High fidelity Reaction volume (µl) 50
Primer I (µM) 10 1.5 Primer I 444
Primer II (µM) 10 1.5 Primer II 445 Template volume (µl) 2
Primer III (µM) 10 0 Primer III # Extra
Primer IV (µM) 10 0 Primer IV # Number of samples 3 1
µl pr. reaction µl to mix Added Cycling parameters
Nuclease-free H2O 37.2 148.8 [  ] 94 °C Preheat 120 sec.
PCR buffer 5 20 [  ] 95 °C Melting 30 sec.
MgSO4 1 4 [  ] 55 °C Anealing 30 sec.   No. of cycles 25
dNTP's 1.5 6 [  ] 68 °C Amplifying 7.5 min.
Polymerase 0.3 1.2 [  ] 68 °C Extension 1 min.
Primer I 1.5 6 [  ] 4 °C Storage 100 hrs.
Primer II 1.5 6 [  ]
Primer III 0 0 [  ]
Primer IV 0 0 [  ]
Template 2 To sample tubes only
Total volume 48 192 → Add 48 µl PCR mix to each sample tube
Comments:
PCR to mutate 5HT7b YFP with primers 444 and 445. Control reaction from Gene Tailor Site-Directed Mutagenesis system kit is carried out 
simultaneously (control plasmids + control primers). The control primers were declared 100 ng/µl each from the manufacturer. Therefore 1.5 µl 
of primer mix and 1.5 µl of nuclease-free H2O were added.
Unmethylated plasmid 5HT7b YFP 6 ng/µl, methylated plasmid 5HT7b YFP and methylated control plasmid from 17.01.07 were used.
Order of addition:
1:Nuclease-free H2O 2:dNTP 3:MgSO4 4:PCR buffer 5:polymerase 6:Primers 7:templat (outside the RNA-lab)
4) 45 µl reaction mix + 1.5 µl ctrl. primer mix + 1.5 µl nuclease-free H2O + 2 µl control Plasmid (outside the RNA-lab)
5) 48 µl reaction mix with primers 444+445 + 2 µl of methylated 5HT7b YFP
6) 48 µl reaction mix with primers 444+445 + 2 µl of unmethylated 5HT7b YFP
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3.3.3 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a powerful and sensitive method to amplify a 
selected DNA sequence in vitro by purified, thermostable DNA polymerases. These 
polymerases synthesize new polynucleotides complementary to an existing DNA or RNA 
template. 
 
In a mix of  the four deoxynucleotides (dATP, dTTP, dCTP and dGTP), primers, correct 
buffer and salt concentration, a thermostable DNA polymerase can replicate a DNA template 
in repeated rounds of replication. The polymerase is guided to the sequence to be copied by 
short synthetically produced oligonucleotide primers that anneal to the DNA at both flanks of 
the desired DNA sequence. These primers induce replication of each strand of the original 
DNA. 
 
PCR reaction is a two or three step reaction which is controlled by temperature regulation. 
First, the reaction mixture is heated to 94ºC. At this temperature the hydrogen bonds that hold 
together the polynucleotides of the double helix are broken, so the target DNA becomes 
denatured into single-stranded molecules. In the second step, the temperature is reduced to 50-
60ºC which allows the primers to anneal to their corresponding DNA sequence. Finally, the 
temperature is increased to the optimum of the polymerase, usually between 68-72ºC, where 
the DNA sequence of interest is replicated in both directions. In a two-step PCR reaction the 
annealing and extension occur at the same temperature.  
 
The reaction steps are repeated for 30-40 cycles by an automated temperature-cycler. 
Theoretically, in a 100 % efficient reaction, every cycle doubles the amount of DNA 
synthesized in the previous cycle, and within a few cycles the predominant product is a single 
species of DNA fragment whose length corresponds to the distance between the two primers. 
 
Usually, the products are analyzed by agarose gel electrophoresis, which will reveal a single 
band if the PCR proceeded as expected and has amplified a single segment of the target DNA. 
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Figure 7. The polymerase chain reaction (Adapted from Genomes 3, © Garland Science 2007). 
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3.3.4 Method II: Standard mutagenesis strategy 
For this mutagenesis strategy both the forward and reverse primers were designed with the 
mutation. The mutagenesis primers were designed for introducing a cutting site for the 
endonuclease BsiWI (…CGTACG…) in extracellular loop 1 in the receptors. The 
mutagenesis primers were supplied by the same manufacturer (Invitrogen®). 
 
In this method two sets of PCR were run. In the first set of PCR (PCR-I), two separate 
reactions were carried out for each plasmid. The wild type 5-HT receptor plasmids were used 
as templates along with one of the mutagenesis primers and a flanking primer in each 
reaction, comprising two reactions for each plasmid. The PCR products obtained were 
separated on agarose gel and purified.  
In the second PCR (PCR-II), the PCR products from PCR-I serve as templates and the 
flanking primers from PCR-I were used to initiate the DNA synthesis. The following flanking 
primers and mutagenesis primers were used to perform the PCR reactions. 
 
 h5-HT4(b) receptor: 
465: h5HT4b EL1 U 1252C 1255A 1257G 
GCC CTT TGG TGC CAT TGA GCT cGT aCg AGA CAT C 
135: Flanking primer (reverse) 
TCA GTC GGC AGA CCA GC 
478: h5HT4b EL1 L 1252C 1255A 1257G 
CTC CCC ATA AAT CCA GAT GTC TcG TaC gAG CTC AAT 
150: Flanking primer (forward) 
TAA TAC GAC TCA CTA TAG GG 
 
h5-HT7(b) receptor: 
468: h5HT7b EL1 U 466T 467A 468C 
GTC AGC GTC ACC GAC CTC ATC Gta cGC AAG TGG ATC TTT GG 
119: Flanking primer (reverse) 
GAA CAG AAA GCA GCC ACC 
481: h5HT7b EL1 L 466T 467A 468C 
TGT CCA AAG ATC CAC TTG CGt acG ATG AGG TC 
115: Flanking primer (forward) 
CGC GAT GAT GGA CGT TAA CAG C 
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Protocol:  
In a microfuge tube kept on ice mixed the following with one mutagenesis primer and one 
flanking primer per reaction for each plasmid and run the PCR for all the four reactions. 
 
PCR-I 
Ingredients μl per reaction Final Conc. 
Nuclease free water 18  
Termopol buffer (10x) 3 1 x 
dNTP (10 μM) 3 1 μM 
DMSO 2 6.7 % 
Vent ® Polymerase 2U/μl 1 0.06 U 
Forward Mutagenesis primer (10 μM) 1 0.3 μM 
Reverse Flanking primer (10 μM) 1 0.3 μM 
Template (Plasmid DNA) 1  
Total reaction mix volume 30  
 
The four products from PCR – I reaction were separated on an agarose gel and purified. These 
products served as templates for the PCR-II reaction.  
PCR-II 
Ingredients μl per reaction Final Conc. 
Nuclease free water 23  
Termopol buffer (10x) 5 1 x 
dNTP (10 μM) 5 1 μM 
DMSO 2 4.0 % 
Vent ® Polymerase 2U/μl 1 0.04 U 
Forward Flanking primer  (10 μM) 2 0.4 μM 
Reverse Flanking primer  (10 μM) 2 0.4 μM 
Template 1 (PCR product I) 5  
Template 2 (PCR product I) 5  
Total reaction mix volume 50  
 
The following figure (figure 8) summarizes the two sets of PCRs giving the final mutated 
DNA products. These mutated products are the DNA coding regions for the two receptors 5-
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HT4(b) and 5-HT7(b). These mutated DNA products and their respective plasmids are cut by 
endonucleases and their DNA fragments ligated together.  
 
 
 
Figure 8. Standard Mutagenesis Strategy (Adapted from Technical Note 5.2, Genomes 3, © Garland 
Science 2007). 
 
The plasmid 3x HA 5-HT4(b) and the mutated DNA product coding the DNA of 5-HT4(b) are 
cut by endonucleases NheI and ClaI and their DNA fragments ligated together. The plasmid 
5-HT7(b) YFP and the mutated DNA product coding the DNA of 5-HT7(b) are cut by 
endonucleases BlpI and XhoI their DNA fragments ligated together. The ligated products 
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obtained are the plasmids containing the cutting site for the endonuclease BsiWI in the 
extracellular loop 1. 
 
3.4 AGAROSE GEL ELECTROPHORESIS  
Agarose gel electrophoresis is performed to identify and separate the DNA fragments. 
Agarose dissolves upon heating to the boiling point and forms a gel when cooled. Agarose gel 
is a fine network of linear polysaccharide molecules which are suitable for separating DNA 
fragments from 200 bp to 50 kb.   
 
At neutral pH, DNA is negatively charged and in an electrical field it will migrate towards the 
positive electrode (cathode). The migration rate of DNA in the gel is dependent on the 
conformation and size of DNA, agarose concentration, buffer concentration and voltage. To 
determine the sizes of the separated DNA molecules, the samples are compared to the DNA 
standard (DNA Ladder) which is run on the same gel. The DNA Ladder consists of DNA 
fragments of known sizes which serve as good markers in the agarose gel electrophoresis. The 
gel is preloaded with the UV-fluorophore ethidium bromide (EtBr) which intercalates 
between the basepairs of the DNA double helix, and allows the DNA fragments to be 
visualized under the exposure of UV-light.           
 
In this study agarose gel electrophoresis was used for two purposes, to identify and isolate the 
PCR products for transformation into DH5αTM- T1R and TOP10 E. coli cells, and to separate 
and purify the restriction digestion products for ligation reaction. 
 
Protocol: 
1. For a 0.8 % gel, dissolve 0.8 g agarose in 100 ml 1x TAE buffer (0.04 M Tris-acetate and 
0.001 M EDTA). 
2. Heat the solution in a microwave until the agarose dissolves completely.  
3. Let the solution cool to about 50-60 ºC and add 20 μl of 2.5 μg/μl ethidium bromide. Pour 
the warm solution into a gel mould fitted with the appropriate comb. Remove the air bubbles 
and allow the gel to set at room temperature. 
4. Transfer the gel to an electrophoresis chamber, cover it with 1x TAE buffer and remove the 
comb. 
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5. Add 6x Loading buffer to the samples (PCR products) and DNA standards (100 bp Ladder 
and 1 kb Ladder; Invitrogen®). The volume of loading buffer is adjusted to achieve 1x 
loading buffer in the final sample.  
6. Load the DNA standards and samples into separate gel wells and run the electrophoresis at 
100 V (Power Pac 200, Bio-Rad Laboratories Inc.) for 1-2 hours. 
7. Visualize the DNA in the gel under UV-light. Excise the agarose gel slice containing the 
desired DNA fragment and extract the DNA from the gel (3.4). 
 
3.5 EXTRACTION OF DNA FROM AGAROSE GELS 
Isolation and purification of DNA fragments from agarose gel was performed using QIAquick 
Gel Extraction Kit (QIAGEN). The principle of the procedure is to solubilise the agarose gel 
in the presence of a chaotropic salt (NaClO4) which breaks the hydrogen bonds in the agarose 
polymer. The solution is then filtered through a column of silica particles which bind DNA at 
a high salt concentration. Binding of DNA to the silica particles is optimal at pH 7.5. QG 
buffer which contains a pH indicator indicates optimal pH by turning the solution yellow at 
this pH range. The DNA is washed with an ethanol containing solution and eluted from the 
column by adding nuclease-free water or a buffer at low salt concentration. 
 
Protocol: 
1. Add 3 volumes of solubilisation buffer QG to 1 volume of excised gel slice. Incubate at 50 
ºC for 10 minutes or until the gel slice has completely dissolved. Vortex the tubes every 2-3 
minutes during the incubation. 
2. Add 1 gel volume of isopropanol to the sample and mix. Addition of isopropanol increases 
yield of DNA fragments of <500 bp and >4 kb. 
3. Place a QIAquick spin column in a provided 2 ml collection tube. Apply the sample to the 
QIAquick column and centrifuge at 13,000 rpm in a tabletop microcentrifuge for 1 minute. 
Discard the flow-through and re-insert the column into the collection tube. 
4. To wash, add 0.75 ml of Buffer PE to QIAquick column. Let stand for 5 minutes and 
centrifuge for 1 minute. Discard the flow-through and centrifuge for an additional minute. 
5. Place the QIAquick column into a new sterile 1.5 ml microcentrifuge tube. Elute the DNA 
by adding 50 μl of nuclease-free water onto the centre of the spin column. Centrifuge the 
column at maximum speed for 1 minute. Store at -20 ºC.  
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The linear mutated plasmid is now ready to be transformed into the bacterial cells. 
  
3.6 PLASMID PROPAGATION 
When a linear plasmid is transformed into a bacterial cell, the host cell circularizes the linear 
plasmid. The plasmids are also replicated independently of chromosomal DNA and thus 
transformation can also be used to produce high numbers of copies of plasmid constructs. The 
bacterial cells used for transformation are strains of Escherichia coli which are pre-treated 
with various chemicals to become competent for DNA transformation. In this study the linear 
mutagenesis plasmids were transformed into both DH5αTM-T1R E. coli and TOP10 
Chemically Competent E. coli cells, both from Invitrogen®. 
 
The transformed bacteria were grown on selective medium (LB medium with agar containing 
antibiotic ampicillin 100μg/ml). The pcDNA 3.1 vector contains a gene coding for ampicillin 
resistance, therefore only the bacteria that are transformed with this vector will survive in this 
medium. The plasmid DNA is isolated using either small- or large-scale plasmid preparations. 
In this study Wizard® Plus SV Miniprep Kit (Promega) was used for small-scale and the 
HiSpeed Plasmid Maxi Kit (Qiagen) was used for large-scale plasmid preparations.  
 
3.6.1 Transformation 
Competent cells are highly sensitive to changes in temperature or mechanical lysis caused by 
pipetting. Transformation should be started immediately after thawing the cells on ice. Mixing 
should be done by swirling or tapping the tube gently, not by pipetting. Heat shock treatment 
of the cells was used to increase DNA uptake. 
 
Protocol: 
1. Pipet 5 μl plasmid DNA from each mutagenesis reaction mixture directly into each vial (50 
μl) of cells and mix gently.  
2. Incubate on ice for 15 minutes. 
3. Heat shock the cells at 42 ºC for 30 seconds without shaking. 
4. Incubate on ice for 1 minute. 
5. Add 250 μl of pre-warmed SOC medium to each vial and mix gently.  
6. Incubate the cells in a horizontal shaker at 37 ºC, 200 rpm for 30 minutes. 
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7. Label and warm the LB agar plates containing 100 μg/ml ampicillin for about 30 minutes in   
   a 37 ºC incubator.     
8. Aliquot 50, 100 and 150 μl from each transformation vial onto the labelled LB agar plates 
and spread it on the plate. 
9. Invert the plates and incubate overnight at 37 ºC. 
10. Pick 9 isolated colonies and inoculate each colony in 10 ml LB medium containing 100 
μl/ml ampicillin. 
11. Grow overnight at 37 ºC in a shaker incubator for small-scale plasmid preparation (3.5.2) 
 
3.6.2 Small-scale plasmid preparation 
For small-scale isolation and purification of plasmids from transfected E. coli cells, the 
Wizard® Plus SV Miniprep kit from Promega® was used. This system provides a simple and 
rapid isolation of plasmid DNA.  
 
The bacterial cells are lysed with a solution containing NaOH and SDS. By neutralising and 
increasing the salt concentration, the chromosomal DNA, cell membrane components and 
denatured proteins will precipitate, while plasmid DNA remains intact in the solution. 
 
An alkaline protease solution is added to inactivate endonucleases and to degrade proteins 
non-specifically. These steps prevent contamination of chromosomal DNA breakdown 
products or plasmid digestion products by endonucleases, and it also decreases the overall 
contamination of proteins in the final product. The plasmid-containing lysate is run through a 
silica-based membrane which binds the plasmid DNA. To elute the contaminants, the 
membrane is washed with ethanol containing high salt concentration. Finally, the plasmid 
DNA is eluted in Nuclease-free Water. 
 
Protocol: 
1. Harvest 10 ml of overnight bacterial culture by centrifugation for 5 minutes at 10,000 x g in 
a tabletop centrifuge. Discard the supernatant. 
2. Add 250 μl of Cell Resuspension Solution and completely resuspend the cell pellet by 
vortexing. 
3. Add 250 μl of Cell Lysis Solution and mix by inverting the tube 4 times. 
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4. Add 10 μl of Alkaline Protease solution and mix as above. Incubate for 5 minutes at room 
temperature. 
5. Add 350 μl of Neutralisation Solution and mix as above. 
6. Centrifuge the bacterial lysate at 14,000 x g in a microcentrifuge for 10 minutes at room 
temperature. 
7. Decant the cleared lysate into Miniprep Spin Column inserted into a 2 ml collection tube. 
Centrifuge at 14,000 x g for 1 minute at room temperature. Discard the flow-through. 
8. Add 750 μl Column Wash Solution, previously diluted with 95 % ethanol, to the spin 
column. Centrifuge as above and discard the flow-through. 
9. Repeat the wash procedure using 250 μl of Column Wash Solution. Centrifuge at 14,000 x 
g for 2 minutes and discard the flow-through. 
10. Transfer the column to a sterile 1.5 ml microcentrifuge tube and elute the plasmid DNA 
by adding 100 μl nuclease-free water to the spin column. Centrifuge at 14,000 x g for 1 
minute at room temperature. Store at -20 ºC. 
To determine the yield, DNA concentration should be determined by both UV 
spectrophotometry at 260 nm and qualitative analysis on an agarose gel.  
 
3.7 QUANTIFICATION OF DNA 
Quantification of DNA was performed by UV spectrophotometric analysis. Nucleotide 
spectra are complicated to analyse quantitatively because they have many non-bonded 
electrons with indistinct transitions giving a multitude of absorptions between 200 nm and 
300 nm. All nucleotides do however have a λ max near 260 nm which is fairly specific for the  
purine and pyrimidine bases. This wavelength can thus be used to estimate the nucleic acid 
concentration in a sample. DNA also absorbs light at 230 nm and 280 nm, but to a lesser 
extent. Pure DNA samples should have the following absorption ratios: 
 
 OD260 / OD280 ratio ~ 1.8-1.9 
 OD260 / OD230 ratio ~ 1.8-2.2  
 
The amount of DNA was calculated by using the following formula:              
 
 DNA (μg/μl) = OD260 x dilution/20 
UV spectrophotometer: Ultrospec 2100 pro UV/Visible spectrophotometer, GE Healthcare. 
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3.8 SUB-CLONING 
In this context, sub-cloning means moving an insert from one vector to another. The method 
involves preparation of inserts and vectors by digesting with restriction enzymes, separation 
and isolation of the DNA fragments by agarose gel electrophoresis and subsequent ligation. 
The method was used to move the desired coding region of h5-HT7 receptor into the specific 
coding region of h5-HT4 receptor and vice versa. 
 
3.8.1 Restriction digestion 
Sequence specific DNA endonucleases (restriction enzymes) were used to prepare vectors and 
inserts for subcloning. These enzymes degrade DNA molecules by breaking the 
phosphodiester bonds that link one nucleotide to the next. The enzymes used were all type II 
restriction endonucleases. These enzymes recognise specific sequences of four to eight 
nucleotides and cut double stranded DNA with either “sticky” (with 5' or 3' overhang) or 
“blunt” ends (no overhang). The choice of buffer is crucial for cutting the DNA with 
specificity and accuracy. The optimal temperature is usually 37 ºC. One unit (1 U) of a 
restriction enzyme is defined as the amount of enzyme that cuts 1 μg of λ-phage DNA in one 
hour. For digestion of circular DNA, 4-5 U per μg of DNA is required.  
 
Protocol: 
1.  Mix the following solution in a microcentrifuge tube kept on ice: 
~ 1 μg/μl plasmid DNA, adjust volume to contain totally 5 μg plasmid DNA 
5 μl 10x assay buffer 
2 μl of each restriction digestion enzyme (10 U/ μl) 
Nuclease-free H2O ad 50 μl 
2. Incubate at 37 ºC for 1 hour. 
3. Perform agarose gel electrophoresis to separate digestion products. 
 
The endonuclease enzyme BsiWI (New England Biolabs®) cuts the gene coding the 
serotonin receptors 3xHA-5HT4 and 5HT7b YFP in the extracellular loop 1 or 2 according to 
where the cutting site is introduced by mutation. Endonuclease enzyme XbaI (New England 
Biolabs®) cuts the plasmid after the coding region of the serotonin receptor genes. 
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Agarose gel electrophoresis was used to identify and separate the restriction cut DNA 
fragments of interest. If the two bands of the expected size (the size of the insert and cut 
vector) were visible upon UV-irradiation of the gel, they were excised and purified by gel 
extraction. The DNA fragments of the two receptors were interchanged and ligated to give a 
recombinant DNA which codes for the chimeric receptors of interest. 
 
3.8.2 Ligation of the restriction digestion products 
The vectors and inserts that were made under restriction digestion reaction and separated by 
agarose gel electrophoresis were ligated by T4 DNA ligase. T4 DNA ligase catalyzes the 
formation of a phosphodiester bond between the 3´-hydroxyl and the 5´-phosphate groups in 
nicked DNA. This reaction requires presence of NAD+ and special buffer conditions. 
Stochiometrical parameters may also affect ligation specificity and efficacy. 
T4 DNA ligase has optimal activity at 37 ºC, but at this temperature the hydrogen bonded 
joint between the sticky ends is unstable. A compromise between rate of enzyme action and 
association of the sticky ends has to be made, and has been established to be in the range of 4-
16 ºC. 
 
Protocol: 
1. Mix 60 fmol insert, 20 fmol vector (3:1 molar ratio) and nuclease-free H2O to a total 
volume of 8.5 μl in a microcentrifuge tube kept on ice. 
2. Add 1 μl of 10x ligase buffer (Fermentas Inc.) 
3. Add 0.5 μl of T4 DNA ligase (1U/μl). Incubate at 16 ºC for 12 hours. 
 
The ligated products can be used immediately for transformation to produce small- or large-
scale plasmid preparations, or stored at -20 ºC until use. 
 
In this study the ligated products were transformed to produce a high copy number of 
plasmids, isolated by large-scale plasmid preparation (3.8). 
 
3.9 LARGE-SCALE PLASMID PREPARATION 
To produce larger amounts of purified plasmid DNA, large-scale plasmid preparation was set 
up using HiSpeed Plasmid Maxi kit (QIAGEN®). The lysis principle is the same as for small-
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scale plasmid preparations. RNase A is added at the beginning of the procedure to digest the 
liberated RNA as to minimise RNA contamination. The lysate is run through an anion-
exchange column consisting of silica beads with high density of diethylaminoethyl (DEAE) 
groups. In acidic environment the DEAE groups become positively charged and interact with 
negatively charged molecules, such as phosphate groups of the RNA and DNA backbone. 
Impurities such as RNA, protein, carbohydrates and other small molecules are washed off 
with medium-salt buffer, while plasmid DNA is eluted with salt buffer. The plasmid eluate is 
concentrated and desalted by isopropanol precipitation. 
 
Protocol:  
1. Prepare a starter culture of 2-5 ml LB medium containing 100 μg/ml ampicillin and 
incubate overnight at 37 ºC in a shaker incubator. 
2. Dilute the starter culture 1/500 in LB medium by adding 1 ml of the starter culture in 500 
ml LB medium containing 100 μg/ml ampicillin. Incubate overnight (12-16 hours) at 37 ºC in 
a shaker incubator. 
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15 minutes at 4 ºC. Decant the 
supernatant. 
4. Resuspend the bacterial pellet in 10 ml buffer P1. 
5. Add 10 ml of buffer P2 and mix thoroughly by inverting the tube 4-6 times. Incubate at 
room temperature for 5 minutes. 
6. Add 10 ml of chilled P3 buffer and mix immediately by inverting the tube 4-6 times. Pour 
the lysate into the capped barrel of a QIAfilter Cartridge and incubate for 10 minutes at room 
temperature. 
7. Equilibrate a HiSpeed Maxi Tip by applying 10 ml buffer QBT. 
8. Remove the cap from the QIAfilter outlet nozzle, gently insert the plunger and filter the cell 
lysate into the HiSpeed Maxi Tip. 
9. Wash the HiSpeed Maxi Tip with 60 ml buffer QC. 
10. Elute DNA with 15 ml buffer QF. 
11. Precipitate DNA by adding 10.5 ml isopropanol. Mix and incubate at room temperature 
for 5 minutes. 
12. Filter the eluate / isopropanol mixture through a QIAprecipitator Maxi Module 
(membrane filter) attached to a 30 ml syringe. Discard the flow-through. 
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13. Wash the DNA with 2 ml 70 % ethanol. Dry the membrane by pressing air through the 
QIAprecipitator quickly and forcefully. Repeat this step. 
14. Attach the QIAprecipitator to a 5 ml syringe and elute DNA into a 1.5 ml sterile 
microcentrifuge tube by adding 700 μl buffer TE. Transfer the eluate back to the syringe and 
elute for a second time into the same 1.5 ml tube to ensure that maximum amount of DNA in 
the QIAprecipitator is solubilised and recovered. Store at -20 ºC. 
 
3.10 DNA SEQUENCING 
DNA of the recombinant plasmids were sequenced to verify whether the inserts and vectors 
were correctly ligated and whether the sequence was intact. The sequencing was performed 
by the staff at the molecular microbiology laboratory of Institute of Microbiology. The 
instrument used for DNA sequencing is ABI Prism 310 Genetic Analyzer (Applied 
Biosystems). 
 
Four different nucleotides with their respective fluorescent probe are used. Each probe is a 
dideoxynucleotide (ddNTP) and a linear amplification reaction will incorporate the probes 
and unmarked deoxynucleotides (dNTP) to the growing sequence of DNA polymerisation. 
Since ddNTP lack a free 3'-hydroxyl group, the synthesis is terminated when ddNTP is 
incorporated instead of dNTP. The sample is separated by capillary electrophoresis (CE) and 
driven through a capillary filled with a polymer (POP6) by high voltage. The polymer will 
slow migration of molecules according to increasing length so that small molecules will be 
least retarded and elute first. The fluorescence is recorded by a laser beam at the end of the 
capillary. Each probe has its own colour coding, so that the sequence can be read manually on 
the output of the ABI prism program (Applied Biosystems). 
 
The following primers were used for the sequencing reaction of the recombinant DNA of the 
two chimeric receptors.  
 
Chimeric receptor: 5-HT7 up to EL1, 5-HT (4b) from EL1 
Forward primers: 
115: 5’ CGC GAT GAT GGA CGT TAA CAG C 3’ 
150 (T7 primer): 5’TAA TAC GAC TCA CTA TAG GG 3’ 
Reverse primers 
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128: 5’ TTA CGC CAT CTG CTG CCA 3’ 
135: 5’TCA GTC GGC AGA CCA GC 3’ 
204 (pcDNA3.1 RSP*): 5’ TAG AAG GCA CAG TCG AGG 3’ 
 
Chimeric receptor: 3xHA-5-HT4 up to EL1, 5-HT7(b) YFP from EL1 
Forward primers: 
150 (T7 primer): 5’TAA TAC GAC TCA CTA TAG GG 3’ 
155: 5’ GAT GGT GGC TGT GTG CTG 3’ 
Reverse primers: 
119: 5’ GAA CAG AAA GCA GCC ACC 3’ 
120: 5’ TAT GCC TTC TTC AAC CGG 3’ 
204 (pcDNA3.1 RSP*): 5’ TAG AAG GCA CAG TCG AGG 3’ 
 
 
The recombinant plasmids were also analyzed qualitatively by restriction digestion and 
separation on agarose gel. The expected fragments from restriction digestion will give an 
indication of the construction of the plasmid. 
 
Both DNA sequencing and agarose gel analysis confirms the plasmid construction. 
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4. RESULTS 
This thesis is based on previous studies and findings of cellular mechanisms of the different 
receptors co-expressed in HEK293 cells (in the Department of Pharmacology and Center for 
Heart Failure Research, University of Oslo, Norway), which revealed that the serotonin 
receptor 5-HT7, when expressed in HEK293 cells, attenuated the signalling through 
endogenous Gs-coupled receptors such as β-AR and EPR  (Andressen et al., 2006). The 
ultimate aim of this line of research is to identify the molecular determinants for this property 
of the 5-HT7 receptor by molecular biology techniques. As an initial guide to identify the key 
amino acids of the 5-HT7 receptor responsible for the attenuation of signalling through other 
Gs-coupled receptors, chimeric receptors were constructed using plasmids encoding the 5- 
HT7(b) receptor and 5-HT4(b) receptor. By comparison of the 5-HT4(b) and 5-HT7(b) receptor 
sequences, DNA sequences were identified corresponding to the first, second and third 
extracellular loops of the receptors, where a cutting site for the restriction endonuclease 
enzyme BsiWI could be introduced at corresponding sites in the two receptors. Different 
mutagenesis strategies were then employed to introduce the cutting sites for the endonuclease 
enzyme BsiWI on the plasmids encoding the 5-HT4(b) and 5-HT7(b)  receptors. First, 
mutagenesis of extracellular loop 2 was carried out by mutagenesis method I (“Gene TailorTM 
Site- Directed Mutagenesis System”, Invitrogen®). Second, mutagenesis of extracellular loop 
1 was carried out by mutagenesis method II (“standard method”). Due to time constraints, 
mutagenesis of extracellular loop 3 was not carried out. The mutated 5-HT receptor plasmids 
were cut in the cutting site introduced in the extracellular loop by BsiWI and after the coding 
regions of the receptors by XbaI. The cut fragments were interchanged and ligated to yield 
plasmids encoding the chimeric receptors. 
 
 
 4.1 DESIGNED MUTAGENESIS PRIMERS  
Mutagenesis primers were designed for all the three extracellular loops of both the 5-HT4(b) 
and 5-HT7(b) receptor plasmids. The following primers were designed for the mutagenesis 
reaction to introduce a cutting site for the restriction endonuclease enzyme BsiWI 
(…CGTACG…) in the extracellular loops 1, 2 and 3 of the plasmids encoding each 5-HT 
receptor. 
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The mutagenesis primers of h5-HT4(b) receptor : 
465: h5-HT4(b) EL1 U 1252C 1255A 1257G 
5’ GCC CTT TGG TGC CAT TGA GCT cGT aCg AGA CAT C 3’ 
 
478: h5-HT4(b) EL1 L 1252C 1255A 1257G 
5’ CTC CCC ATA AAT CCA GAT GTC TcG TaC gAG  CTC AAT 3’ 
450: h5-HT4(b) EL2 – mut- L45 
5’ CGT AGA GTT AGA GTT CTG GTc GtA CgT CCT CTT TTC TAT CAA ATC 3’ 
451: h5-HT4(b) EL2 – nomut-U41 
5’ ACC AGA ACT CTA ACT CTA CGT ACT GTG TCT TCA TGG TCA AC 3’ 
479: h5-HT4(b) EL3 U 1862G 1865C 1866G 
5’ CAC CAA TAT TGT GGA TCC TTT CgT Acg CTA CAC TG 3’ 
480: h5-HT4(b)EL3 L 1862G 1865C 1866G 
5’ GGG ACA GTG TAG CgT Acg AAA GGA TCC ACA ATA 3’ 
 
The mutagenesis primers of h5-HT7(b) receptor : 
468: h5-HT7(b)EL1 U 466T 467A 468C 
5’ GTC AGC GTC ACC GAC CTC ATC Gta cGC AAG TGG ATC TTT GG 3’ 
481: h5-HT7(b)EL1 L 466T 467A 468C 
5’ TGT CCA AAG ATC CAC TTG CGt acG ATG AGG TC 3’ 
448: h5-HT7(b) EL2 – nomut- L33 
5’ GCC CAT CCA AAG AGT GGA GGT AAG GTG ATG GAG 3’ 
449: h5-HT7(b) EL2 –mut-U34 
5’ CCT CCA CTC TTT GGA TGG GCT CcG tAc GTA AAT G 3’ 
482: h5-HT7(b) EL3 U 1095C 1097T 1100G 
5’ CAG ACC CTT CAT CTG TcG tAC gTC CTG CAG CTG CAT C 3’ 
483: h5-HT7(b) EL3 L 1095C 1097T 1100G 
5’ GCT GCA GGA cGt ACg ACA GAT GAA GGG TCT GG 3’ 
484: h5-HT7(b)YFP 1516 L25 
5’ AAC TTC AGG GTC AGC TTG CCG TAG G 3’ 
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4.2 MUTAGENESIS IN EXTRACELLULAR LOOP 2  
(MUTAGENESIS METHOD I) 
The mutation in the plasmid encoding the extracellular loop 2 of the 5-HT4(b) and 5-HT7(b) 
receptors was made by the mutagenesis primers in a polymerase chain reaction using method 
I (“Gene TailorTM Site- Directed Mutagenesis System”, Invitrogen®).  According to the 
manufacturer’s primer design specifications only one of the primer pair contains the mutation. 
The plasmids which were used for the mutagenesis reaction are 5-HT7(b) YFP and 3xHA-5-
HT4(b).  
 
Figures 9 and 10 show the mutations made in the plasmids to introduce a cutting site for the 
endonuclease BsiWI. The mutations led to changes in the amino acid sequences in the 
extracellular loop 2 of the 5-HT receptors.  
 
 
   
Figure  9. The figure shows the exact location in the 5-HT4(b)  receptor where a restriction site for the 
endonuclease enzyme BsiWI was introduced and later used for cutting and religating the 5-HT7(b) 
receptor. The arrows in the figure show the amino acids K(Lysine), F(Phenylalanine) and 
N(Asparagine) replaced by amino acids T(Threonine),Y(Tyrosine) and D(Aspartate) due to mutations. 
Adapted from (Kaumann and Levy, 2006a) with modification. 
 
 
  Results 
 41
 
 
 
Figure 10. The figure shows the exact location in the 5-HT7(b)  receptor where a restriction site for the 
endonuclease enzyme BsiWI was introduced and later used for cutting and religating the 5-HT4(b) 
receptor. The arrows in the figure show the amino acids Q(Glutamine) and N(Asparagine) replaced by 
amino acids P(Proline) and Y(Tyrosine) due to mutations. Adapted from (Heidmann et al., 1997) with 
modification. 
 
 
The polymerase chain reaction gave linear double-stranded DNA containing mutations. The 
linear double-stranded DNA was transformed into “TOP10” E.coli bacteria where it was 
circularized. Nine colonies of each plasmid were grown in culture tubes for small scale 
plasmid preparation. Only seven of the culture tubes containing 5-HT7(b)YFP and five culture 
tubes containing 3xHA-5-HT4(b) had dense growth and were chosen for the small-scale 
isolation and purification.  
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4.2.1 Restriction digestion in extracellular loop 2 
The purified mutated plasmids were cut in the DNA encoding the extracellular loop 2 by the 
endonuclease enzyme BsiWI and after the coding region of the 5-HT receptor coding 
sequences by XbaI. The sizes of the DNA fragments were 653 bp (insert) and 5967 bp (cut 
vector) for the 3xHA-5-HT4(b) and 1409 bp (insert) and 6084 bp (cut vector) for the 5-
HT7(b)YFP ( Fig.11).  
 
 
Figure 11. The restriction digestion products of 3xHA-5-HT4(b) and 5-HT7(b)YFP cut with BsiWI /XbaI 
were separated on agarose gel (0.8 %). The samples in lanes 2-8 are restriction digestion products of 5-
HT7(b)YFP and in lanes 10-14 are the restriction digestion products of 3xHA-5-HT4(b). Lane 9 is an  
uncut 5-HT7(b)YFP. 1 kb DNA Ladder as markers are run in lane 1 and 15. 
 
The samples which gave the best separation on the gel of the DNA fragments from each 
plasmid were chosen for purification and ligation. The insert (653 bp) from 3xHA-5-HT4(b) 
was ligated into the cut vector (6084 bp) of 5-HT7(b)YFP and the insert (1409 bp) from 5-
HT7(b)YFP was ligated into the cut vector (5967 bp) of 3xHA-5-HT4(b). The ligated products 
were transformed into “TOP10” E.coli bacteria and the recombinant DNA was amplified. 
The constructed chimeric receptor DNA was sequenced to verify if the DNA fragments were 
correctly inserted. The sequencing result revealed a deletion of ~10bp in the beginning of the 
5-HT7(b)YFP coding region in both the mutated 5-HT7(b)YFP plasmid and in the derived 
chimeric construct. For unknown reasons, the opposite chimeric construct did not reveal any 
interpretable sequence and neither of the chimers had the correct, intact sequences either. 
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Since this mutagenesis method did not give a satisfactory result we decided to use the 
standard mutagenesis strategy to make mutations in extracellular loop 1. 
 
4.3 MUTAGENESIS IN EXTRACELLULAR LOOP 1  
(MUTAGENESIS METHOD II) 
The mutation in the extracellular loop 1 by method II (standard mutagenesis strategy) was 
made by the mutagenesis primers and flanking primers in two sets of polymerase chain 
reaction.According to standard mutagenesis strategy the mutation was made in both the 
forward and reverse primers. The plasmids used were 5-HT7(b)YFP and 3xHA-5-HT4(b). 
 
Figures 12 and 13 show the mutations made in the plasmid DNA to introduce a cutting site for 
the endonuclease BsiWI. The mutation led to changes in the amino acid sequences in the 
extracellular loop 1 of the 5-HT receptors.  
 
Figure 12. The figure shows the exact location in the 5-HT4(b)  receptor where a restriction site for the 
endonuclease enzyme BsiWI was introduced and later used for cutting and religating the 5-HT7(b) 
receptor. The arrow in the figure shows the amino acid Q (Glutamine) replaced by amino acid R 
(Arginine) due to mutations. 
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Figure 13. . The figure shows the exact location in the 5-HT7(b)  receptor where a restriction site for the 
endonuclease enzyme BsiWI was introduced and later used for cutting and religating the 5-HT4(b) 
receptor. The arrows show the amino acids G (Glycine), G (Glycine) are replaced by V (Valine) and R 
(Arginine) due to mutations. Adapted from (Heidmann et al., 1997) with modification. 
 
 
4.3.1 Restriction digestion in extracellular loop 1 
The mutated plasmids are cut in the DNA encoding the extracellular loop 1 by the restriction 
endonuclease BsiWI, and after the coding region of the 5-HT receptor coding sequences by 
XbaI. The sizes of the DNA fragments were 931 bp (insert) and 5689 bp (cut vector) for the 
3xHA-5-HT4(b) and 1645 bp (insert) and 5848 bp (cut vector) for the 5-HT7(b)YFP, 
respectively (Fig.14). 
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Figure 14. The restriction digestion products of 3xHA-5-HT4(b) and 5-HT7(b)YFP cut with BsiWI 
/XbaI were separated on agarose gel (1.0 %). The sample in lane 2 are the restriction digestion 
products of 5-HT7(b)YFP. The sample in lane 4 are the restriction digestion products of 3xHA-5-HT4(b). 
In lane 1 & 5 are the 100 bp DNA Ladder and in lane 3 the 1 kb DNA Ladder. 
 
The BsiWI/XbaI- fragment (931 bp) of  3xHA-5-HT4(b) was ligated into the BsiWI/XbaI cut 
vector (5848 bp) of 5-HT7(b)YFP, whereas the BsiWI/XbaI-fragment (1645 bp) of  5-HT7(b)YFP 
was ligated into the BsiWI/XbaI cut vector (5689 bp) 3xHA-5-HT4(b), respectively. The ligated 
products were subsequently transformed into “TOP10” E.coli bacteria and the recombinant 
DNA was amplified. 
 
The chimeric receptor DNAs were sequenced to verify if the DNA fragments were correctly 
inserted. The sequencing result revealed that the chimers had correct and intact sequences. 
Fig.15 illustrates the chimers made. 
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Figure 15. The figure shows the chimeric receptors 5-HT4 up to EL1, 5-HT7(b) from EL1 and 5-HT7 up 
to EL1 and 5-HT4(b) from EL1. (Designed by Cam Hong Thi Nguyen, 2007). 
 
Figure 15 is an illustration of the chimeric receptors made at the molecular level. Only the 
plasmids containing the recombinant DNA for the chimers were constructed. These plasmids 
containing the constructed chimeric receptor DNA will subsequently be expressed in HEK293 
cells to produce the chimeric receptor proteins of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5-HT4(b)5-HT7(b) 
5-HT4 up to EL1, 5-HT7(b) from EL1     5-HT7 up to EL1, 5-HT4(b) from EL1 
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The following graphic maps show the plasmids containing the recombinant gene for the   
chimers made. 
 
 
 
Figure 16. Graphic map of the plasmid containing the chimeric receptor gene 3xHA-5-HT4 up to EL1, 
5-HT7(b) YFP from EL1.  
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Figure 17. Graphic map of the plasmid containing the chimeric receptor gene 5-HT7 up to EL1, 5-
HT4(b) from EL1. 
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5. DISCUSSION 
5.1 PURPOSE OF 5-HT7(b) RECEPTOR MUTAGENESIS AND 
CONSTRUCTION OF CHIMERIC RECEPTORS 
The 5-HT7 receptor is the most recently identified member of the 5-HT receptor family.  
Much is yet unknown about this receptor subtype. So far a couple of studies have revealed the 
existence of three isoforms of the human 5-HT7 receptor (5-HT7a,b,d), which differ in their C-
termini. To date, these isoforms show no major differences in their respective pharmacology 
and signal transduction properties (Heidmann et al., 1998;Krobert et al., 2001).  
 
The present study of constructing chimers was designed based on data from previous studies 
revealing that the 5-HT7 receptor when co-expressed with other Gs-coupled receptors in 
HEK293 cells attenuate the signalling through the other receptors (Bruheim et al., 
2003;Andressen et al., 2006). The purpose of constructing chimeric 5-HT7/5-HT4 receptors is 
to elucidate the structural basis for this attenuating property of the 5-HT7 receptor. Since the 
5-HT4(b) receptor does not posses this kind of attenuating property we decided to use this 
receptor to construct different chimers with the 5- HT7(b) receptor.  
 
The mutagenesis reactions to introduce cutting sites for the endonuclease enzyme BsiWI on 
the plasmids encoding the 5-HT receptors were carried out by two different methods. Method 
I (“Gene TailorTM Site-Directed Mutagenesis System”) was initially chosen and was tried 
with several different modifications, but eventually resulted in a product lacking 10 bp. 
Method II (standard mutagensis strategy) was therefore chosen for the second mutagenesis 
and was successful, enabling construction of the desired chimeric receptor constructs. 
 
5.2 MUTAGENESIS REACTION IN EXTRACELLULAR LOOP 2 BY 
METHOD I 
The mutation in extracellular loop 2 was performed using the “Gene TailorTM Site-Directed 
Mutagenesis System”, according to the protocol from Invitrogen®. It was very difficult to 
perform the mutagenesis reaction initially. Several PCR attempts were made and different 
PCR parameters were changed in order to optimize the conditions for a successful mutation of 
the plasmids. 
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According to the manufacturer’s protocol the plasmids should first be methylated and then 
amplified in a polymerase chain reaction with the mutagenesis primers. The procedure 
worked well for the plasmid 3xHA-5-HT4(b) (6620 bp) but it was ineffective for the plasmid c-
myc-5-HT7(a) (6795 bp). 
 
The plasmid c-myc-5-HT7(a) was the one we initially used for the mutagenesis reaction. Many 
attempts were made to mutate the plasmid c-myc-5-HT7(a) with different PCR enzymes 
(Accuprime™ Pfx, Platinum® Taq and Platinum® Taq HiFi) and with different cycling 
conditions such as amplifying time, number of cycles etc. None of the PCR reactions gave 
any product, so we decided to use the plasmid 5-HT7(b)-YFP (7493 bp) instead of plasmid c-
myc-5-HT7(a). 
 
The mutagenesis reaction was made both on methylated and unmethylated 5-HT7(b)-YFP 
plasmid. The analysis of the mutagenesis products on agarose gel showed a single band in the 
sample containing the unmethylated plasmid 5-HT7(b)-YFP. A few attempts were made to 
mutate the methylated 5-HT7(b)-YFP plasmid with Vent® DNA polymerase and Platinum® 
Taq HiFi . Analysis on agarose gel showed no band in the sample containing methylated 
plasmid. We therefore decided to use the unmethylated mutated 5-HT7(b)-YFP plasmid further 
for the restriction digestion reaction. 
 
5.2.1 The purpose of methylation reaction 
The plasmid DNA is methylated in a methylation reaction prior to the mutagenesis reaction 
by PCR. The enzyme DNA methylase methylates cytosine residues within a specific sequence 
throughout the double-stranded DNA of the original plasmid (template). When the PCR 
product is transformed into E. coli bacteria, the bacteria digest the methylated template DNA 
with an endonuclease enzyme called McrBC leaving only unmethylated, mutated product. 
The purpose of this procedure is to increase the signal-to-noise ratio, i.e. the relative 
frequency of mutated plasmids. However, for us it resulted instead in loss of efficiency and 
we were not able to obtain any product from the methylated plasmids. Apparently, this step is 
not necessary, since we were successful in obtaining a product from non-methylated plasmid, 
although, unfortunately, this plasmid was lacking a stretch of 10 bp. 
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5.2.2 Mutagenesis primers 
Design of good mutagenesis primers is very critical for the PCR. Only good primers will yield 
specific and effective amplification of the target gene, and at the same time avoid 
amplification of any unwanted DNA sequences due to primer dimers or unspecific binding of 
the primer. We carried out a couple of control reactions to test the mutagenesis primers by 
running a PCR with the known primers from the Levy laboratory (which gives a PCR product 
of 300-500 bp)  along with the designed primers and on both the tagged plasmids and the wild 
type receptor plasmids. All the designed mutagenesis primers functioned well.   
 
5.2.3 Magnesium ion concentration in the PCR 
The significance of the chemistry of the Mg2+ ion to the enzymes lies in the unusual reaction 
chemistry of the ion to fulfil a range of functions. Mg2+ interacts with substrates, enzymes and 
occasionally both (Mg2+ may form part of the active site). Some enzymes do not need any 
additional components to show full activity but DNA polymerase requires magnesium ion as a 
co-factor to function efficiently. DNA polymerase is an enzyme that catalyzes the 
polymerization of deoxyribonucleotides in DNA synthesis and the magnesium ion either 
alters the conformation of the enzyme or takes part in the chemistry of the catalytic reaction. 
In the absence of the magnesium ion or when the magnesium ion concentration is very low 
the DNA polymerase does not function well at all. The manufacturer’s protocol denotes that 
the methylation reaction buffer also contains magnesium ions, and that it is therefore 
sufficient to add 1 μl of 50 mM MgSO4 per 50 μl mutagenesis reaction mixture for the 
methylated plasmid, as opposed to 2 μl for the unmethylated plasmid.  
 
Though many attempts were made to mutate the plasmids and perform the restriction 
digestion with subsequent ligation the sequencing results revealed that the sequence of the 
mutated 5-HT7(b)-YFP were not intact. Ten bases were deleted in the final mutated 5-HT7(b)-
YFP plasmid.  
 
There are several different possible reasons for the deletion of 10 bases. One of the reasons 
could be that Taq DNA polymerase could have put the wrong bases in that region during 
DNA replication and the proof reader just removed those bases. Alternatively the magnesium 
concentration in the PCR mix was too low for the polymerase to function efficiently. Another 
Discussion 
 52
reason could probably be the exposure of the DNA in the agarose gel to UV-light while 
examining the gel. Ultraviolet radiation is an ionising radiation and depending upon its 
intensity it exerts its effects on DNA by point, insertion and/or deletion (nicking) mutations. 
UV radiation of 260 nm induces dimerisation of adjacent pyrimidine bases, especially if these 
are both thymines, resulting in a cyclobutyl dimer. Other pyrimidine combinations also form 
dimers. UV-induced dimerisation usually results in a deletion mutation when the modified 
strand is copied (Genomes, 2ndedition, T.A. Brown). 
 
Longer exposure of the plasmid DNA to alkaline protease during the DNA purification 
(Wizard® Plus SV Miniprep Kit, Promega) might lead to some nicking of the plasmid DNA. 
Alkaline protease (an enzyme that degrades proteins) inactivates endonucleases and other 
proteins released during the lysis of the bacterial cells that can adversely affect the quality of 
the isolated DNA. If the bacterial culture is incubated for more than 5 minutes with alkaline 
protease then nicking of the plasmid may occur. 
 
One possible explanation why only one of the two plasmids (3xHA-5-HT4(b)) was able to be 
methylated and the other (5-HT7(b)-YFP) not is may be because the two plasmids had different 
origin and therefore the differences in the construction of the plasmids might have an impact 
for the methylation reaction. The plasmid 5-HT7(b)-YFP (7493 bp) is also bigger in size 
compared to the 3xHA-5-HT4(b) (6620 bp). 
 
Since the mutagenesis reaction according to the protocol from Invitrogen® resulted in a final 
product with a deletion, we decided to use method II (standard mutagenesis strategy) for the 
next chimer construct. 
 
5.3 MUTAGENESIS REACTION IN EXTRACELLULAR LOOP 1 BY 
METHOD II 
This mutagenesis strategy is a commonly used strategy to make mutations in the DNA. Using 
this strategy we were able to introduce a cutting site for the enzyme BsiWI in the extracellular 
loop 1, followed by restriction digestion and ligation.  
 
In this PCR protocol we used Vent® polymerase with termopol buffer. Vent® polymerase is 
a high-fidelity thermophilic DNA polymerase with an intergral 3’→5’ proofreading 
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exonuclease activity. The polymerase also tolerates a wide range of cosolvents and in this 
protocol DMSO was used as a cosolvent. 
 
DMSO is a polar aprotic solvent that dissolves both polar and nonpolar compounds and is 
miscible in a wide range of organic solvents as well as water. This solvent is used in the PCR 
to reduce secondary structures in the DNA template or the primers. At the same time this 
solvent also seems to increase the mutation rate in PCR. 
 
Though two sets of PCR were run to mutate the plasmids this method gave the correct and 
intact chimeric receptor sequences and proved to be an easier way to induce mutation for 
larger plasmids. Since this mutagenesis method seems to be more reliable than method I 
perhaps the other chimers could be made using this method. 
 
5.4 PREVIOUS FINDINGS ON THE ATTENUATING PROPERTY OF 
THE 5-HT7 RECEPTORS  
Many studies have indicated that the amino acid sequences of IC loop 3 and the C-terminus 
are the main sites for coupling to G proteins in a variety of GPCRs, and thus these receptor 
domains are the most critical domains for the signal transduction. However, it is completely 
unknown which parts of the 5-HT7 receptor are causing the attenuation of signalling by other 
Gs-coupled receptors. We have some indications based on unpublished data from our group 
(in collaboration with Evelien Gellynck and Peter Vanhoenacker from Ghent, Belgium) that 
when the IC loop 3 and the C-terminus of the 5-HT7 receptors were removed the receptors did 
not couple efficiently to adenylyl cyclase but the receptor was still able to attenuate signalling 
through other Gs-coupled receptors (β-adrenergic receptors and prostaglandin receptors). 
Thus, these receptor domains do not seem to affect the preassociation of the 5-HT7 receptors 
with Gs, presuming this preassociation is related to the attenuation of signalling through other 
Gs-coupled receptors. It is also believed that other domains of the 5-HT7 receptors could be 
involved in the preassociation with Gs.  
 
Constructing and expressing a series of chimeric receptors could reveal the key amino acid 
sequences which are involved in the preassociation of the 5-HT7 receptors with Gs. 
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5.5 CHIMERIC RECEPTORS 
Many studies have been done in the recent years using chimeric receptors to determine the 
structural basis for the receptor function in agonist binding and selectivity of G protein 
activation. In this study we are interested in determining the molecular basis for the 
attenuating property of the 5-HT7 receptor by constructing and testing a series of chimers of 
the 5-HT7 and 5-HT4 receptors. 
 
We decided to construct the chimers by introducing restriction sites to allow “cutting and 
pasting” in the extracellular domains.  To date, there is not much data available concerning 
the property of the 5-HT7 receptor which we are interested in (attenuation of signalling by 
other Gs-coupled receptors), and therefore it was not obvious where in the receptors to “cut 
and paste”. One reason to start with the extracellular domains was to leave the intracellular 
loops intact, since it seems likely that they are somehow involved in the attenuation, either 
alone or in combination. So far only the chimers fused in extracellular loop 1 have been 
successfully made. The attempt of constructing the chimers fused in extracellular loop 2 was 
unsuccessful, due to the 10-bp deletion as described above. The chimers fused in extracellular 
loop 3 will be constructed in the future and tested along with the chimers made in this study. 
 
In order to construct these chimers we had to mutate one or two amino acids to introduce the 
cutting site for the endonuclease enzyme. If these amino acids are the  key amino acids for the 
normal functioning of the 5-HT7 receptor, this change of amino acids will have an impact on 
the receptor behaviour (either a loss of function or an unusual behaviour) when expressed in 
mammalian cells (for example HEK293). It would be relevant to test the properties of the 5-
HT7 and 5-HT4 receptors mutated in the extracellular domains in addition to testing the 
chimeric receptors, to check the importance of introducing these amino acid changes. 
Alternatively, the chimeric receptors could be “corrected” by mutagenesis to change the 
sequence around the fusion site back to the original amino acids (in other words make the 
mutation on other amino acids away from the one which was initially mutated). 
 
Only when the attenuating property of the various chimeric receptors are correlated with the 
5-HT4 and 5-HT7 amino acid sequences of these chimeric receptors, it is possible to assign the 
functional properties to specific structural domains of the receptors. For a more detailed 
resolution of the precise amino acid sequences involved in the attenuating property one could 
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insert a smaller segment of the 5-HT7 receptor sequence into the 5-HT4 receptor or by 
substituting single amino acids.  
 
5.6 CHIMERIC RECEPTORS VS OTHER STRATEGIES 
To use chimeric receptors to understand the structural basis for the receptor function is one 
approach. Among a few other strategies to study the receptor function, the split receptor 
strategy gives a clue of the importance of certain receptor domains. Split receptor has been 
studied to explore the role of different hydrophobic domains of the GPCR receptors. Split 
receptors are mainly made by inserting a termination codon after an amino acid that encodes a 
hydrophobic domain or in the intracellular / extracellular loop. Split receptors could also be 
made by deleting different loop regions of the receptor. 
 
In a study made on β2-AR by B.K. Kobilka et al. (Kobilka et al., 1988) the receptor was 
expressed as two separate peptides, one encoding amino acid 1- 262, containing hydrophobic 
domains 1 to 5, SR (1-5), and the other containing hydrophobic domains 6 to 7, SR (6-7). It 
was possible to express SR (1-5) and SR (6-7) together in Xenopus oocytes and obtain a 
functional receptor, but injecting mRNA for SR (6-7) alone did not lead to the expression of 
the protein in the oocyte membranes. 
 
The mutant SR (1-5) did not bind ligands or activate adenylyl cyclase, but the mutant SR (6-
7) was able to activate the adenylyl cyclase although the activation was only ~ 25 % as 
efficient as the wild-type β2-AR. The conclusion of the study was that although the 
hydrophobic domain 7 (or 6 and 7) seemed to be the major determinant(s) of β2-AR in 
activating adenylyl cyclase, this region of the molecule alone was inefficient to bind β2-AR 
ligands or activate adenylyl cyclase. 
 
A majority of studies also used deletion mutation to understand the structural basis of a 
receptor function. The premise in these studies was that there is a single motif within GPCRs 
which is largely responsible for G protein activation and selectivity and therefore the deletion 
of this domain would uncouple GPCR from G protein. This assumption, while used 
successfully to identify functional domains for many single membrane-spanning biomolecules 
such as kinase superfamily, must be taken with caution for the GPCRs. Because GPCRs have 
seven-membrane-spanning architecture which allows the intracellular loops to interact with 
Discussion 
 56
each other in forming a functional domain(s) to interact with G protein, deletion of a single 
domain can not conclude about the receptor activity or function. The interpretation of the data 
from deletion studies will therefore lead to some uncertainty.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Summary and conclusions 
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6. SUMMARY AND CONCLUSIONS 
The ultimate aim of the present series of studies is to determine the key amino acid sequences 
of the 5- HT7 receptor which are responsible for the attenuation of signalling through other 
Gs-coupled receptors. 
 
Many studies on chimeric receptors have given valuable data on the structural basis for the 
receptor function of several other GPCRs.  Chimeric receptors seem to be a more convincing 
strategy than for example deletion studies to gain knowledge about the structural determinants 
which are crucial for a receptor function and thus to understand the cellular mechanisms. 
Deletion mutation studies has many disadvantages such as loss of function of the receptor, 
change in the overall folding of the receptor protein at the intracellular regions of the receptor 
which are important for the preassociation of Gs etc. Chimeric receptors may not have these 
disadvantages since the functional response of the chimers will be linked with both the 
receptors (5-HT4(b) and 5-HT7(b) ). 
 
In further studies of chimeric 5-HT4(b)/5-HT7(b) receptors the results will be interpreted on the 
basis that of the two receptors only one (5-HT7(b)) possesses the attenuating property while the 
other receptor (5-HT4(b)) does not.  
 
The function of specific structural domains of the 5-HT7 receptor will only be determined 
when the chimers are expressed in HEK293 cells and their pharmacological properties 
determined by ligand binding and adenylyl cyclase assays. 
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8. APPENDIX 
8.1 GENE TAILOR™ SITE-DIRECTED MUTAGENESIS SYSTEM-KIT 
CONTENTS  
 
Components 
DNA methylase (4 units/μl) 
Methylation buffer 
200x SAM 
dNTP mix (10 mM each) 
Control Plasmid (100 ng/ μl) 
Control Primers (10 μM each) 
Sterile, distilled water 
One-Shot® MAX Efficiency® DH5α™ -T1R 
 
* Patent pending 
 
 
8.2 BUFFERS AND SOLUTION 
 
Buffer Ingredients 
Buffer P1 50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 μg/ml RNase A 
Buffer P2 200 mM NaOH 
1 % SDS 
Buffer P3 3.0 M potassium acetate pH 5.5 
Buffer QBT 750 mM NaCl 
50 mM MOPS pH 7.0 
15 % isopropanol 
0.15 % Triton®-X-100 
Buffer QC 1.0 M NaCl 
50 mM MOPS pH 7.0  
1.5 % isopropanol 
Buffer QF 1.25 M NaCl 
50 mM Tris-HCl pH 8.5 
15 % isopropanol 
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dNTP Mix, 10 mM 10 mM of dATP, dGTP, dCTP, dTTP 
LB-medium 10 g/l tryptone 
5 g/l yeast extract 
10 g/l (170mM) NaCl 
adjusted to pH 7 
LB- plates LB- medium 
15 g/l Bacto-agar  
Loading buffer 6X 0.25 % bromophenol blue 
0.25 % xylene cyanol FF 
15 % Ficoll in dH2O 
NE buffer 3 10x 100 mM NaCl 
50 mM Tris-HCl                                        
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 at  25°C 
 
NE buffer 4 10x 50 mM potassium acetate
20 mM Tris-acetate 
10 mM Magnesium Acetate
1 mM Dithiothreitol 
pH 7.9 at 25°C 
 
SOC 20 g/l tryptone 
5 g/l yeast extract 
10 mM NaCl 
10 mM MgCl2 
10 mM MgSO4 
2.5 mM KCl 
20  mM glucose 
TAE 0.04 M Tris- acetate 
0.001 M EDTA 
TE (membrane)buffer 50 mM Tris-HCl, pH 7,5 at 20۫C  
1 mM EDTA 
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 Thermopol buffer 10x 10 mM KCl 
10 mM (NH4)2 SO4 
20 mM Tris-HCl (pH 8.8 at 25ºC) 
2 mM MgSO4 
0.1 % Triton X-100 
Washing buffer  
 
50 mM Tris-HCl, pH 7.0 at 20 ۫C 
2 mM MgCl2. 
Wizard Plus SV Minipreps Cell 
Resuspension Solution 
50 mM Tris-HCl pH 7.5 
10 mM EDTA 
100 μg/ml RNase A 
Wizard Plus SV Minipreps Cell Lysis 
Solution 
0.2 M NaOH 
1 % SDS 
Wizard Plus SV Minipreps 
Neutralization Solution 
4.09 M guanidine hydrochloride 
0.759 M potassium acetate 
2.12 M glacial acetic acid 
Wizard Plus SV Minipreps Column 
Wash Solution 
60 % ethanol(v/v) 
162.8 mM potassium acetate 
27.1 mM Tris-HCl, pH 7.5 
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8.3 MANUFACTURERS: CHEMICALS AND CLONING MATERIALS 
 
Chemical/cloning materials Abbreviation Manufacturer 
100bp DNA ladder  Invitrogen 
1kb DNA ladder  Invitrogen 
AccuPrime Pfx DNA Polymerase  Invitrogen 
Agar  AppliChem 
Agarose for gel electrophoresis  Camber 
BlpI  NE Biolabs 
BsiWI  NE Biolabs 
ClaI  NE Biolabs 
DH5α™ -T1R E.coli  Invitrogen 
Dimethylsulfoxide DMSO Sigma 
Ethidium bromide EtBr Sigma 
Ethylendiaminetetraacetic acid, Disodium salt, 
Dihydrate, approx. 99% 
EDTA Sigma 
Gene Tailor™ Site-Directed Mutagenesis System  Invitrogen 
HiSpeed plasmid maxi kit  Qiagen 
Isopropanol  Arcus 
KpnI  Invitrogen 
Magnesium sulphate MgSO4 Invitrogen 
Mutagenesis primers  Invitrogen 
NheI  NE Biolabs 
QIAquick Gel Extraction Kit   Qiagen 
Platinum Taq DNA polymerase   Invitrogen 
Platinum Taq HiFi   Invitrogen 
QIAquick GEL Extraction KIT  QIAGEN 
SOC- medium  Invitrogen 
Sodium chloride solution, 0.9% NaCl, 0.9% Braun 
Sodium hydroxid NaOH Applichem 
T4 DNA ligase  Fermentas Inc. 
10X buffer for T4 DNA ligase   Fermentas Inc. 
Thermopol Reaction buffer  NE Biolabs 
TOP-10 Chemically competent E.coli cells  Invitrogen 
TOPO TA Cloning  Invitrogen 
Tryptone  AppliChem 
Vent® polymerase  NE Biolabs 
Wizard®Plus SV Miniprep Kit  Promega 
XbaI  NE Biolabs  
XhoI  NE Biolabs 
Yeast Extract  AppliChem 
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8.4 INSTRUMENTS  
 
Instruments Manufacturer 
ABI Prism 3730 DNA Analyzer  Applied Biosystems 
Power Pac 200  Bio-Rad Laboratories Inc. 
PTC-100 Programmable Thermal Controller MJ Research, Inc. 
Ultrospec 2100 pro UV/ Visible spectrophotometer GE Healthcare 
 
 
